薬物スクリーニング市場- 世界の産業規模、シェア、動向、機会、予測、製品・サービス別、サンプルタイプ別、エンドユーザー別、地域別、競合別、2019年～2029年

世界の薬物スクリーニング市場は、2023年に52億8,000万米ドルと評価され、2029年までのCAGRは5.25%で、予測期間中に着実な成長を予測しています。

世界の薬物スクリーニング市場には、尿、血液、唾液、毛髪などの生体サンプル中の薬物またはその代謝物の存在を検出するために設計されたさまざまな製品とサービスが含まれます。これらのスクリーニングは、ヘルスケア、雇用、スポーツ、法執行など多様な分野で極めて重要です。この市場の特徴は、既存プレーヤーと新興プレーヤーの両方が存在し、それぞれが薬物スクリーニング技術の開発と革新に貢献していることです。

技術の進歩は、薬物スクリーニング市場の進化において極めて重要な役割を果たしています。質量分析法やイムノアッセイ法などの高度な分析技術の統合により、薬物検査の感度と精度が大幅に向上しました。ポイント・オブ・ケア検査の急速な発展と自動化の利用も、スクリーニング・プロセスの効率化と合理化に貢献しています。従来の尿検査は、経口液検査によって補完され、場合によっては取って代わられつつあります。経口液採取は非侵襲的であり、最近の薬物使用を検出できるため、職場検査や路上薬物検査など、さまざまな用途で魅力的な選択肢となっています。薬物乱用の結果についての意識の高まりと、政府や組織による厳しい規制の実施が、薬物スクリーニング・サービスの需要を促進しています。輸送や建設など安全が最優先される業界では、規制要件により従業員の定期的な薬物検査が義務付けられています。

主な市場促進要因

ヘルスケア支出の増加が世界の薬物スクリーニング市場を牽引しています。

意識向上と教育プログラムの増加が薬物スクリーニングの世界市場を牽引

主な市場課題

サンプルの完全性と不純物混入

主な市場動向

技術の進歩

セグメント別洞察

製品サービス別洞察

サンプルタイプ別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の薬物スクリーニング市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品サービス別（薬物スクリーニング製品、分析機器、迅速検査機器、経口液検査機器、消耗品、薬物スクリーニングサービス）
  • サンプルタイプ別（尿サンプル、呼気サンプル、口腔液サンプル、毛髪サンプル、その他サンプル）
  • エンドユーザー別（薬物検査ラボ、職場、刑事司法・法執行機関、病院、薬物治療センター、個人ユーザー、疼痛管理センター、学校・大学）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 製品サービス別
  • サンプルタイプ別
  • エンドユーザー別
  • 地域別

第6章 北米の薬物スクリーニング市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品サービス別
  • サンプルタイプ別
  • エンドユーザー別
  • 国別

第7章 欧州の薬物スクリーニング市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品サービス別
  • サンプルタイプ別
  • エンドユーザー別
  • 国別

第8章 アジア太平洋の薬物スクリーニング市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品サービス別
  • サンプルタイプ別
  • エンドユーザー別
  • 国別

第9章 南米の薬物スクリーニング市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品サービス別
  • サンプルタイプ別
  • エンドユーザー別
  • 国別

第10章 中東アフリカの薬物スクリーニング市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品サービス別
  • サンプルタイプ別
  • エンドユーザー別
  • 国別

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品上市

第13章 競合情勢

• Quest Diagnostics Inc.
• Heska Corporation
• Thermo Fisher Scientific, Inc.
• Alfa Scientific Designs, Inc.
• OraSure Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• MPD Inc.
• Shimadzu Corporation
• Lifeloc Technologies, Inc.
• Dragerwerk AG Co. KGaA
• Premier Biotech, Inc.
• Omega Laboratories, Inc.

第14章 戦略的提言

第15章 免責事項

Global Drug Screening Marketwas valued at USD 5.28 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. The Global Drug Screening Market encompasses a range of products and services designed to detect the presence of drugs or their metabolites in biological samples such as urine, blood, saliva, and hair. These screenings are crucial in diverse sectors, including healthcare, employment, sports, and law enforcement. The market is characterized by the presence of both established and emerging players, each contributing to the development and innovation in drug screening technologies.

Technological advancements play a pivotal role in the evolution of the drug screening market. The integration of advanced analytical techniques, such as mass spectrometry and immunoassay methods, has significantly enhanced the sensitivity and accuracy of drug testing. Rapid developments in point-of-care testing and the use of automation are also contributing to more efficient and streamlined screening processes. Traditional urine testing is being complemented and, in some cases, replaced by oral fluid testing. The non-invasive nature of oral fluid collection and the ability to detect recent drug use make it an attractive option for various applications, including workplace testing and roadside drug testing. Increasing awareness about the consequences of drug abuse and the implementation of stringent regulations by governments and organizations are driving the demand for drug screening services. In industries where safety is paramount, such as transportation and construction, regulatory requirements mandate regular drug testing of employees.

Key Market Drivers

Rising Healthcare Expenditure is Driving the Global Drug Screening Market

An escalating factor in healthcare spending is the aging demographic. The World Health Organization (WHO) projects a doubling of the global population aged 60 and above by 2050, compared to 2015 figures. This demographic shift correlates with a heightened vulnerability to chronic ailments, prompting a greater emphasis on preventive healthcare strategies, early disease detection, and personalized treatment approaches. Chronic conditions like diabetes, cardiovascular disorders, and cancer are on an upward trajectory worldwide, driving up demand for healthcare services and accentuating the importance of efficient, timely screening protocols. Drug screening, pivotal in early disease identification and management, plays a pivotal role in alleviating strain on healthcare systems.

Escalating healthcare spending has catalyzed investments in research and development, yielding innovative strides in drug screening technologies. Advanced methodologies like liquid biopsy, genetic profiling, and high-throughput screening offer swifter, more precise results. These advancements bolster diagnostic proficiency, enabling healthcare practitioners to pinpoint diseases in nascent stages when interventions are most efficacious. Governments and healthcare entities globally acknowledge the value of preventive healthcare in mitigating burgeoning costs. Drug screening emerges as a linchpin in preventive strategies, empowering healthcare providers to identify at-risk individuals or those in incipient disease phases. Timely interventions not only enhance patient outcomes but also mitigate long-term financial burdens on healthcare infrastructures.

The global drug screening sector experiences robust expansion, propelled by heightened demand for efficacious diagnostic tools and the prioritization of preventive healthcare. Industry leaders channel investments into research and development, unveiling innovative solutions that broaden drug screening's application spectrum. The market encompasses diverse segments, encompassing urine, blood, hair, and saliva testing, catering to a myriad of healthcare requisites.

Increased Awareness and Education Programs is Driving the Global Drug Screening Market

In recent years, there has been a significant upsurge in awareness and educational initiatives addressing substance abuse and its societal ramifications. This heightened awareness has not only spurred increased efforts in prevention and treatment but has also served as a catalyst for driving growth in the global drug screening market. As societies become more cognizant of the consequences of drug abuse, there is a heightened demand for effective screening tools to ensure safety across various environments. Governments, non-profit organizations, and private entities worldwide are making substantial investments in educational campaigns aimed at raising awareness about the detrimental effects of substance abuse. These initiatives target diverse demographics, including schools, workplaces, and communities, offering insights into the impact of substance abuse on health, relationships, and overall well-being.

A key outcome of these awareness endeavors is a shift in societal attitudes towards drug use. As individuals become better informed, there is a growing emphasis on prevention and early intervention. Consequently, employers, educational institutions, and healthcare providers are increasingly incorporating drug screening programs as proactive measures to address substance abuse concerns. In the corporate realm, employers are recognizing the deleterious impact of substance abuse on productivity, safety, and employee welfare. Workplace drug screening initiatives have become integral components of corporate wellness strategies. Through routine drug testing, companies aim to cultivate safe and healthy work environments, mitigating the risk of accidents, absenteeism, and impaired job performance.

Educational establishments are likewise embracing drug screening measures to ensure secure and conducive learning environments. From secondary schools to universities, institutions are implementing random drug testing or screening during admission processes. This serves the dual purpose of identifying potential issues and acting as a deterrent against drug use among students. Beyond workplaces and educational institutions, community programs and sports organizations are leveraging drug screening to uphold safety standards. Athletes, in particular, undergo routine drug tests to uphold the integrity of competitions and safeguard participants' health.

Key Market Challenges

Sample Integrity and Adulteration

Sample integrity refers to the condition and reliability of the specimen collected for drug screening, which is crucial for obtaining accurate test results. Inaccurate or compromised samples can result in false-positive or false-negative outcomes, undermining the integrity of the entire screening process. Factors that can compromise sample integrity include improper collection procedures, contamination, and mishandling during transportation and storage.The first line of defense against compromised results is ensuring proper sample collection procedures. However, challenges arise when individuals attempt to manipulate or adulterate their samples to conceal drug use. This may involve the use of various substances, dilution techniques, or even substituting samples altogether.

Also, once collected, samples must be transported and stored under specific conditions to maintain their integrity. Temperature fluctuations, exposure to light, and inadequate storage conditions can all contribute to sample degradation, potentially leading to unreliable test results.Individuals undergoing drug testing may resort to various adulteration techniques to alter the composition of their samples, posing a constant challenge for drug screening laboratories to detect such manipulations and uphold the integrity of the screening process.

Key Market Trends

Technological Advancements

The landscape of drug screening has undergone rapid evolution due to technological breakthroughs. Innovative and sophisticated techniques are replacing traditional methods, offering improved accuracy, speed, and cost-effectiveness. Automation has revolutionized drug screening workflows by streamlining processes and reducing errors. Robotic systems are used for sample preparation, testing, and result analysis, enhancing overall efficiency in drug screening laboratories. High-throughput screening (HTS) technologies enable the assessment of a large number of compounds in a short time, expediting the drug discovery process. This has become crucial in pharmaceutical research, allowing scientists to evaluate potential drug candidates more rapidly. Miniaturized technologies and microfluidic devices enable researchers to conduct drug screening experiments on a smaller scale, conserving resources and accelerating the screening process to meet high-throughput requirements.

Next-generation sequencing (NGS) technologies have revolutionized genomics and molecular biology, providing valuable insights into drug-genetic interactions. This information is essential for personalized medicine and optimizing drug regimens for individual patients. Artificial intelligence (AI) and machine learning (ML) algorithms are employed to analyze large datasets generated during drug screening. These technologies enhance the prediction of drug interactions, identify potential side effects, and optimize drug development pipelines.

The adoption of these technological advancements has propelled the global drug screening market to new heights, driven by several key factors. The integration of advanced technologies has significantly improved the accuracy and efficiency of drug screening processes, attracting investments from pharmaceutical companies, research institutions, and healthcare providers. Automated processes and high-throughput technologies contribute to cost savings by reducing manual labor and minimizing errors. This cost-effectiveness is a compelling factor for organizations seeking resource optimization. The rapid pace of technological advancements has expedited the drug discovery and development process. Pharmaceutical companies can identify potential drug candidates more swiftly, reducing time-to-market and overall research and development costs. Advances in genomics, combined with AI and ML, have facilitated personalized medicine. Drug screening technologies now consider individual genetic variations, enabling tailored treatment plans and minimizing adverse reactions.

Segmental Insights

Product Services Insights

In the Product Services category, Drug Screening Product emerged as the dominant player in the global Drug Screening market in 2023. These advanced products offer improved accuracy and reliability, reducing the potential for errors associated with traditional testing methods. This significant benefit has led to their widespread adoption across various sectors, including healthcare, transportation, and sports. The increasing prevalence of substance abuse has driven the demand for robust drug screening solutions. Employers, law enforcement agencies, and healthcare providers are increasingly relying on advanced screening products to promptly identify and address drug-related issues.

Strict regulations governing drug testing in workplaces and other settings have made it necessary to use reliable and compliant drug screening products. Companies are inclined to invest in products that adhere to industry standards, ensuring legal compliance and maintaining a safe working environment. Continuous technological advancements, such as the integration of artificial intelligence (AI) and machine learning (ML) algorithms, have empowered drug screening products to provide more accurate and nuanced results. These technologies not only enhance detection capabilities but also streamline the entire testing process.

The convenience offered by portable and user-friendly drug screening devices has further contributed to their market dominance. Employers and individuals appreciate the ease of use and quick turnaround time provided by these products, making them an attractive choice for routine testing.

Sample Type Insights

The Urine Samples segment is projected to experience rapid growth during the forecast period. Urine drug testing is renowned for its high accuracy and reliability. The method can detect a wide range of substances, including both illicit drugs and prescription medications. The extensive detection capabilities make urine samples an ideal choice for comprehensive drug screening programs that aim to identify various substances in an individual's system. Furthermore, urine testing provides a longer detection window compared to other methods. Metabolites of drugs are often present in urine for an extended period, allowing for the detection of substance use over several days or even weeks. This extended window is especially valuable in situations where historical drug use patterns need to be assessed. From a financial standpoint, urine drug testing is often more cost-effective than alternative methods. The ease of sample collection, along with the ability to conduct batch testing, contributes to lower overall costs. This cost-effectiveness has played a pivotal role in driving the widespread adoption of urine samples in drug screening programs across various sectors.

Regional Insights

North America emerged as the dominant player in the global Drug Screening market in 2023, holding the largest market share in terms of value. One of the main reasons for North America's dominance in the global drug screening market is its rapid adoption of advanced technologies. The region has been quick to embrace cutting-edge screening methods, such as liquid chromatography-mass spectrometry (LC-MS) and immunoassay techniques, allowing for more accurate and efficient detection of a wide range of drugs. This commitment to technological innovation has given North American companies a competitive edge, attracting clients from around the world seeking reliable and state-of-the-art drug screening solutions. North America boasts a regulatory environment that prioritizes safety and compliance, especially in critical sectors like healthcare and transportation. Federal and state regulations mandate drug testing in various industries, ensuring a high demand for reliable and efficient screening solutions. This stringent regulatory framework has led to the development of advanced and comprehensive drug testing programs, establishing North American companies as leaders in the provision of reliable testing services.

Key Market Players

Quest Diagnostics Inc.

Heska Corporation

Thermo Fisher Scientific, Inc.

Alfa Scientific Designs, Inc.

OraSure Technologies, Inc.

F. Hoffmann-La Roche Ltd

MPD Inc.

Shimadzu Corporation

Lifeloc Technologies, Inc.

Dragerwerk AG Co. KGaA

Premier Biotech, Inc.

Omega Laboratories, Inc.

Report Scope:

In this report, the Global Drug Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug Screening Market,By Product Services:

• Drug Screening Product
• Analytical Instruments
• Rapid Testing Devices
• Oral Fluid Testing Devices
• Consumables
• Drug Screening Service

Drug Screening Market,By Sample Type:

• Urine Samples
• Breath Samples
• Oral Fluid Samples
• Hair Samples
• Other Samples

Drug Screening Market,By End User:

• Drug Testing Laboratories
• Workplaces
• Criminal Justice and Law Enforcement Agencies
• Hospitals
• Drug Treatment Centers
• Individual Users
• Pain Management Centers
• Schools and Colleges

Drug Screening Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Drug Screening Market.

Available Customizations:

Global Drug Screening market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Drug ScreeningMarketOutlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Product Services (Drug Screening Product, Analytical Instruments, Rapid Testing Devices, Oral Fluid Testing Devices, Consumables, Drug Screening Service)
  • 5.2.2.By Sample Type (Urine Samples, Breath Samples, Oral Fluid Samples, Hair Samples, Other Samples)
  • 5.2.3.By End User (Drug Testing Laboratories, Workplaces, Criminal Justice and Law Enforcement Agencies, Hospitals, Drug Treatment Centers, Individual Users, Pain Management Centers, Schools and Colleges)
  • 5.2.4.By Region
  • 5.2.5.By Company (2023)
• 5.3.Market Map
  • 5.3.1.By Product Services
  • 5.3.2.By Sample Type
  • 5.3.3.By End User
  • 5.3.4.By Region

6.North America Drug Screening Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Product Services
  • 6.2.2.By Sample Type
  • 6.2.3.By End User
  • 6.2.4.ByCountry
    • 6.2.4.1.United States Drug Screening Market Outlook
      • 6.2.4.1.1.Market Size Forecast
      • 6.2.4.1.1.1.By Value
      • 6.2.4.1.2.Market Share Forecast
      • 6.2.4.1.2.1.By Product Services
      • 6.2.4.1.2.2.By Sample Type
      • 6.2.4.1.2.3.By End User
    • 6.2.4.2.Canada Drug Screening Market Outlook
      • 6.2.4.2.1.Market Size Forecast
      • 6.2.4.2.1.1.By Value
      • 6.2.4.2.2.Market Share Forecast
      • 6.2.4.2.2.1.By Product Services
      • 6.2.4.2.2.2.By Sample Type
      • 6.2.4.2.2.3.By End User
    • 6.2.4.3.Mexico Drug Screening Market Outlook
      • 6.2.4.3.1.Market Size Forecast
      • 6.2.4.3.1.1.By Value
      • 6.2.4.3.2.Market Share Forecast
      • 6.2.4.3.2.1.By Product Services
      • 6.2.4.3.2.2.By Sample Type
      • 6.2.4.3.2.3.By End User

7.Europe Drug Screening Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Product Services
  • 7.2.2.By Sample Type
  • 7.2.3.By End User
  • 7.2.4.By Country
    • 7.2.4.1.France Drug Screening Market Outlook
      • 7.2.4.1.1.Market Size Forecast
      • 7.2.4.1.1.1.By Value
      • 7.2.4.1.2.Market Share Forecast
      • 7.2.4.1.2.1.By Product Services
      • 7.2.4.1.2.2.By Sample Type
      • 7.2.4.1.2.3.By End User
    • 7.2.4.2.Germany Drug Screening Market Outlook
      • 7.2.4.2.1.Market Size Forecast
      • 7.2.4.2.1.1.By Value
      • 7.2.4.2.2.Market Share Forecast
      • 7.2.4.2.2.1.By Product Services
      • 7.2.4.2.2.2.By Sample Type
      • 7.2.4.2.2.3.By End User
    • 7.2.4.3.United Kingdom Drug Screening Market Outlook
      • 7.2.4.3.1.Market Size Forecast
      • 7.2.4.3.1.1.By Value
      • 7.2.4.3.2.Market Share Forecast
      • 7.2.4.3.2.1.By Product Services
      • 7.2.4.3.2.2.By Sample Type
      • 7.2.4.3.2.3.By End User
    • 7.2.4.4.Italy Drug Screening Market Outlook
      • 7.2.4.4.1.Market Size Forecast
      • 7.2.4.4.1.1.By Value
      • 7.2.4.4.2.Market Share Forecast
      • 7.2.4.4.2.1.By Product Services
      • 7.2.4.4.2.2.By Sample Type
      • 7.2.4.4.2.3.By End User
    • 7.2.4.5.Spain Drug Screening Market Outlook
      • 7.2.4.5.1.Market Size Forecast
      • 7.2.4.5.1.1.By Value
      • 7.2.4.5.2.Market Share Forecast
      • 7.2.4.5.2.1.By Product Services
      • 7.2.4.5.2.2.By Sample Type
      • 7.2.4.5.2.3.By End User

8.Asia Pacific Drug Screening Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Product Services
  • 8.2.2.By Sample Type
  • 8.2.3.By End User
  • 8.2.4.By Country
    • 8.2.4.1.China Drug Screening Market Outlook
      • 8.2.4.1.1.Market Size Forecast
      • 8.2.4.1.1.1.By Value
      • 8.2.4.1.2.Market Share Forecast
      • 8.2.4.1.2.1.By Product Services
      • 8.2.4.1.2.2.By Sample Type
      • 8.2.4.1.2.3.By End User
    • 8.2.4.2.India Drug Screening Market Outlook
      • 8.2.4.2.1.Market Size Forecast
      • 8.2.4.2.1.1.By Value
      • 8.2.4.2.2.Market Share Forecast
      • 8.2.4.2.2.1.By Product Services
      • 8.2.4.2.2.2.By Sample Type
      • 8.2.4.2.2.3.By End User
    • 8.2.4.3.South Korea Drug Screening Market Outlook
      • 8.2.4.3.1.Market Size Forecast
      • 8.2.4.3.1.1.By Value
      • 8.2.4.3.2.Market Share Forecast
      • 8.2.4.3.2.1.By Product Services
      • 8.2.4.3.2.2.By Sample Type
      • 8.2.4.3.2.3.By End User
    • 8.2.4.4.Japan Drug Screening Market Outlook
      • 8.2.4.4.1.Market Size Forecast
      • 8.2.4.4.1.1.By Value
      • 8.2.4.4.2.Market Share Forecast
      • 8.2.4.4.2.1.By Product Services
      • 8.2.4.4.2.2.By Sample Type
      • 8.2.4.4.2.3.By End User
    • 8.2.4.5.Australia Drug Screening Market Outlook
      • 8.2.4.5.1.Market Size Forecast
      • 8.2.4.5.1.1.By Value
      • 8.2.4.5.2.Market Share Forecast
      • 8.2.4.5.2.1.By Product Services
      • 8.2.4.5.2.2.By Sample Type
      • 8.2.4.5.2.3.By End User

9.South America Drug Screening Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Product Services
  • 9.2.2.By Sample Type
  • 9.2.3.By End User
  • 9.2.4.By Country
    • 9.2.4.1.Brazil Drug Screening Market Outlook
      • 9.2.4.1.1.Market Size Forecast
      • 9.2.4.1.1.1.By Value
      • 9.2.4.1.2.Market Share Forecast
      • 9.2.4.1.2.1.By Product Services
      • 9.2.4.1.2.2.By Sample Type
      • 9.2.4.1.2.3.By End User
    • 9.2.4.2.Argentina Drug Screening Market Outlook
      • 9.2.4.2.1.Market Size Forecast
      • 9.2.4.2.1.1.By Value
      • 9.2.4.2.2.Market Share Forecast
      • 9.2.4.2.2.1.By Product Services
      • 9.2.4.2.2.2.By Sample Type
      • 9.2.4.2.2.3.By End User
    • 9.2.4.3.Colombia Drug Screening Market Outlook
      • 9.2.4.3.1.Market Size Forecast
      • 9.2.4.3.1.1.By Value
      • 9.2.4.3.2.Market Share Forecast
      • 9.2.4.3.2.1.By Product Services
      • 9.2.4.3.2.2.By Sample Type
      • 9.2.4.3.2.3.By End User

10.Middle East Africa Drug Screening Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Product Services
  • 10.2.2.By Sample Type
  • 10.2.3.By End User
  • 10.2.4.By Country
    • 10.2.4.1.South Africa Drug Screening Market Outlook
      • 10.2.4.1.1.Market Size Forecast
      • 10.2.4.1.1.1.By Value
      • 10.2.4.1.2.Market Share Forecast
      • 10.2.4.1.2.1.By Product Services
      • 10.2.4.1.2.2.By Sample Type
      • 10.2.4.1.2.3.By End User
    • 10.2.4.2.Saudi Arabia Drug Screening Market Outlook
      • 10.2.4.2.1.Market Size Forecast
      • 10.2.4.2.1.1.By Value
      • 10.2.4.2.2.Market Share Forecast
      • 10.2.4.2.2.1.By Product Services
      • 10.2.4.2.2.2.By Sample Type
      • 10.2.4.2.2.3.By End User
    • 10.2.4.3.UAE Drug Screening Market Outlook
      • 10.2.4.3.1.Market Size Forecast
      • 10.2.4.3.1.1.By Value
      • 10.2.4.3.2.Market Share Forecast
      • 10.2.4.3.2.1.By Product Services
      • 10.2.4.3.2.2.By Sample Type
      • 10.2.4.3.2.3.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Recent Development
• 12.2.Mergers Acquisitions
• 12.3.Product Launches

13.Competitive Landscape

• 13.1.Quest Diagnostics Inc.
  • 13.1.1.Business Overview
  • 13.1.2.Company Snapshot
  • 13.1.3. Products Services
  • 13.1.4. Financials ( as reported)
  • 13.1.5.Recent Developments
  • 13.1.4.Key Personnel Details
  • 13.1.5.SWOT Analysis
• 13.2.Heska Corporation
• 13.3.Thermo Fisher Scientific, Inc.
• 13.4.Alfa Scientific Designs, Inc.
• 13.5.OraSure Technologies, Inc.
• 13.6.F. Hoffmann-La Roche Ltd
• 13.7.MPD Inc.
• 13.8.Shimadzu Corporation
• 13.9.Lifeloc Technologies, Inc.
• 13.10.Dragerwerk AG Co. KGaA
• 13.11.Premier Biotech, Inc.
• 13.12.Omega Laboratories, Inc.

14.Strategic Recommendations

15.About us Disclaimer